Tirzepatide Cost: Mounjaro vs Zepbound Pricing

Quick Answer

Tirzepatide costs approximately $1,023–$1,059 per month at list price (Mounjaro/Zepbound). With the Lilly Savings Card, eligible commercially insured patients pay $25/month. For self-pay patients, Eli Lilly introduced Zepbound single-dose vials at $399–$549/month — the most affordable branded GLP-1 option for uninsured patients.

Tirzepatide Products and Prices

Product	Indication	Dose	Monthly List Price
Zepbound	Obesity	2.5–15 mg	~$1,059
Mounjaro	Type 2 Diabetes	2.5–15 mg	~$1,023

Unlike semaglutide, all Mounjaro/Zepbound doses (from 2.5 mg starter to 15 mg maintenance) are priced the same — you don't pay more as you titrate upward.

Zepbound Self-Pay Vials: The Breakthrough Cost Option

In late 2024, Eli Lilly introduced Zepbound Single-Dose Vials specifically for self-pay patients — a lower-cost option without the autoinjector pen:

Dose	Self-Pay Vial Monthly Cost
2.5 mg	~$399/month
5 mg	~$499/month
7.5 mg	~$549/month
10 mg	~$549/month
12.5 mg	~$549/month
15 mg	~$549/month

These are available directly through LillyDirect.com and select pharmacies without insurance. Patients draw from the vial with a standard syringe — same medication, different delivery format.

For self-pay patients, this reduces tirzepatide cost from $1,059 to $399–549/month — a 50–60% reduction.

Cost With Insurance and Savings Programs

Lilly Savings Card:

Eligible commercially insured patients: $25/month (Zepbound or Mounjaro)
Maximum savings: up to $573/month off list price
Apply at: Zepbound.com or Mounjaro.com

Medicare Part D:

Mounjaro (diabetes indication): typically covered with cost-sharing
Zepbound: expanding coverage; varies by plan
Lilly insulin value program savings don't typically extend to tirzepatide for Medicare patients

Medicaid:

Mounjaro generally covered for diabetes indication in most states
Zepbound coverage for obesity varies by state Medicaid program

Tirzepatide vs. Semaglutide Cost Comparison

	Tirzepatide	Semaglutide
List price	~$1,059/month	~$1,349/month
With savings card	~$25/month	~$25/month
Self-pay cash option	~$399–549/month	No equivalent
Average weight loss	~21%	~15%
Cost-effectiveness	Higher (more loss, lower price)	Lower

From a value perspective, tirzepatide wins on both dimensions: it's cheaper at list price and produces more weight loss. For self-pay patients, the self-pay vial option further tilts the equation toward tirzepatide.

How to Get Tirzepatide at Lower Cost

Step 1: Check savings card eligibility. If you have commercial insurance, apply for the Lilly Savings Card before your first fill. This is the most important step.

Step 2: Request prior authorization. Your provider submits documentation of your BMI and comorbidities. Appeal if initially denied — success rates for appeals are meaningful.

Step 3: Use the self-pay vials. If uninsured or insurance doesn't cover it, LillyDirect.com's self-pay vials at $399–549/month are the most affordable branded option.

Step 4: Check telehealth platforms. Platforms like Found, Hims, and specialized GLP-1 clinics sometimes have negotiated pricing or bundled options.

Get a Tirzepatide Prescription Online

Bottom Line

Tirzepatide is now the most cost-effective GLP-1 option for most patients: lower list price than Wegovy, savings card brings it to $25/month for insured patients, and self-pay vials ($399–549/month) provide an accessible path for uninsured patients. The combination of lower cost and superior efficacy makes it the clear first choice when cost and access allow.